Gilead Sciences has done some phenomenal things with anti-retroviral drug treatments for HIV and Hepatitis-C Virus (HCV). The big issue with the company from an investment standpoint is whether or not its pipeline contains more blockbusters, and if so, how many. This is a classic case where blindly investing in a low PE Ratio (GILD’s PE Ratio stands at around 7x) can lead to trouble.
Loading...
Reload document 
Open in new tab